Navidea Biopharmaceuticals Investor Relations Material

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing precision immunodiagnostic agents and immunotherapeutics. Its primary technology platform, Manocept, is designed to target the CD206 receptor found on activated macrophages, which plays a key role in diagnosing and treating diseases such as cancer, autoimmune conditions, and inflammatory diseases. The company operates through two main segments: Diagnostic Substances, which include imaging agents, and Therapeutic Development Programs, aimed at therapeutic applications of its platform. Navidea is headquartered in Dublin, Ohio, and its shares are traded on the OTC Markets.